Omeros (OMER) Interest Expenses (2010 - 2026)
Omeros (OMER) posted Interest Expenses of $5.9 million for Q1 2026, down 13.68% sequentially from $6.8 million in Q4 2025, and down 42.32% YoY from $10.2 million in Q1 2025.
Omeros (OMER) Interest Expenses (2010 - 2026) Analysis & Trends
Omeros has reported Interest Expenses for 17 years, with the latest figure at $5.9 million in Q1 2026.
- Quarterly Interest Expenses fell 42.32% year-over-year to $5.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.0 million (down 16.47% YoY) and the FY2025 annual result came in at $182.3 million, up 226.98% from the prior year.
- Interest Expenses fell to $5.9 million in Q1 2026 per OMER's latest filing, from $6.8 million in the prior quarter.
- Over five years, Interest Expenses peaked at $22.0 million in Q4 2023 and troughed at -$10.5 million in Q4 2022.
- A 5-year average of $7.8 million and a median of $7.9 million in 2023 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2022 and 2025: Interest Expenses tumbled 159.41% in 2022, then jumped 573.37% in 2025.
- Over 5 years, Interest Expenses stood at -$10.5 million in 2022, then surged by 308.63% to $22.0 million in 2023, then slumped by 95.39% to $1.0 million in 2024, then surged by 573.37% to $6.8 million in 2025, then retreated by 13.68% to $5.9 million in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $5.9 million, $6.8 million, and $21.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Omeros | 1.24 Bn | 1.24 Bn | 27.73 Mn | 58.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 58.85 Mn |
| Jun 30, 2026 | 58.85 Mn |
| Mar 31, 2026 | 5.89 Mn |
| Mar 31, 2026 | 5.89 Mn |
| Dec 31, 2025 | 6.83 Mn |
| Dec 31, 2025 | 6.83 Mn |
| Sep 30, 2025 | 21.65 Mn |
| Sep 30, 2025 | 21.65 Mn |
| Jun 30, 2025 | 12.87 Mn |
| Jun 30, 2025 | 12.87 Mn |
| Mar 31, 2025 | 10.22 Mn |
| Mar 31, 2025 | 10.22 Mn |
| Dec 31, 2024 | 1.01 Mn |
| Dec 31, 2024 | 1.01 Mn |
| Sep 30, 2024 | 6.17 Mn |
| Sep 30, 2024 | 6.17 Mn |
| Jun 30, 2024 | 9.22 Mn |
| Jun 30, 2024 | 9.22 Mn |
| Mar 31, 2024 | 8.23 Mn |
| Mar 31, 2024 | 8.23 Mn |